%20(1)%20(1).avif)
The regulator that decides whether pharma's AI is safe enough to use has built its own. The FDA launched an internal agentic AI tool, Elsa, in June 2025 and expanded it in 2026 to help staff review protocols, summarize adverse events, and target inspections.
That's not a footnote. It signals where agentic AI in pharma is already headed industry-wide, and it means the agency reviewing a sponsor's AI-assisted submission is running comparable tools on its own side of the desk.
This guide covers agentic AI in pharma specifically, part of the broader picture in Tecla's Agentic AI in Healthcare guide: where literature review, document drafting, and safety monitoring actually run in production today.
What Counts as Agentic AI in Pharma?
Agentic AI in pharma is a system that plans and carries out a multi-step research or regulatory task, drafting a document, triaging a safety case, synthesizing a literature set, rather than answering one question at a time.
A search tool finds relevant papers when someone asks.
An agentic system decides which papers are relevant to a specific regulatory question, cross-references them, and drafts the section of a document that cites them, all before a person requests any individual step.
None of that removes the expert from the loop. It changes what the expert spends their first hour on: reviewing a draft instead of staring at a blank page.
What the FDA's Own Adoption Signals
Elsa runs inside a secure government cloud environment and does not train on data submitted by regulated companies. FDA staff verify every input and output, exactly the same human-in-the-loop pattern the agency expects from industry.
That symmetry matters. A regulator that has built and deployed its own agentic tools understands the failure modes firsthand, hallucinated citations, incomplete context, model drift, because its own reviewers have run into them.
The FDA's January 2025 draft guidance and its January 2026 guiding principles with the European Medicines Agency both reflect that lived experience.
Both set out a risk-based framework tied to how much a given AI use actually influences a decision, not a blanket rule for every use case.
Where Pharma Is Actually Running This in Production
The workflow below covers regulatory document preparation specifically. The sections after it cover literature synthesis, pharmacovigilance, and where a subject matter expert's sign-off still has to sit.
Literature Review and Evidence Synthesis
A systematic literature review that once took a team weeks to compile can be drafted in a fraction of the time when an agent retrieves the relevant studies, extracts the data points a protocol calls for, and organizes them into the required format.
The reviewer's job shifts from compiling to verifying: checking that the agent pulled the right studies, extracted the right numbers, and didn't quietly drop a contradicting result that belonged in the summary.
Pharmacovigilance and Adverse Event Processing
Pfizer has used AI to sort and categorize incoming adverse event case reports since 2014, extracting patient, drug, and event details automatically so safety scientists spend their time on complex causality assessments instead of data entry.
Agentic triage extends that same pattern: an agent reads an incoming report, extracts the required elements, checks it against known signal patterns, and routes anything ambiguous to a safety scientist rather than clearing it alone.
Where Human Sign-Off Still Sits
None of this changes who is accountable for a regulatory filing or a safety determination. A medical writer, a regulatory scientist, or a safety scientist still reviews the output and owns what gets submitted or reported.
The FDA's own framework draws the same line: the more a given output could influence a regulatory decision or a patient's safety, the more rigorous the validation and human review has to be before it moves forward.
Implementation: Guardrails Specific to Pharma
Every guardrail below exists to answer one question a regulator will eventually ask: can this organization show exactly how this document or this decision was produced.
Rolling This Out: What to Expect
Literature synthesis and first-draft generation carry the least direct risk and are typically where pharma teams see results fastest, since neither one touches a live patient or a filed document on its own.
Validate the model's outputs against a set of documents with known, confirmed answers before it touches a live submission or case. That validation record is exactly what a regulator will ask to see during an inspection.
Expect the underlying data infrastructure to need work before the model does. An agent drafting from disorganized source systems will draft confidently and incorrectly, which is a harder problem to catch than an agent that simply runs slow.
The Team Behind Production Agentic AI
The FDA built Elsa with its own reviewers embedded at every stage, not as an afterthought. That same discipline, involving the people who will actually use and validate the system, is what separates a pilot from something a sponsor can defend during an inspection.
Tecla's Agentic AI services design, build, and operate these workflows directly, the same document drafting, literature synthesis, and pharmacovigilance systems above, running in your stack with the evals and guardrails production requires.
Or bring the expertise in-house: AI engineers who've worked on live pharma and life sciences systems, past the demo stage.
Tecla runs a network of senior engineers across the US and Latin America, built over more than a decade, with a top 3% acceptance rate and first candidates in 3 to 5 business days.
FAQ
.avif)
.png)
